

Kenneth W Kinzler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/282739/publications.pdf>

Version: 2024-02-01

137
papers

84,215
citations

6124

83
h-index

13635

134
g-index

146
all docs

146
docs citations

146
times ranked

84425
citing authors

#	ARTICLE	IF	CITATIONS
1	TCR-mimic bispecific antibodies to target the HIV-1 reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123406119.	3.3	10
2	An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. Science, 2022, 25, 104437.	1.9	2
3	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine, 2022, 386, 2261-2272.	13.9	337
4	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. Journal of Clinical Oncology, 2022, 40, LBA100-LBA100.	0.8	5
5	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	2.3	77
6	Bispecific antibodies targeting mutant RAS neoantigens. Science Immunology, 2021, 6, .	5.6	106
7	Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	39
8	TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. Science Translational Medicine, 2021, 13, .	5.8	30
9	Targeting a neoantigen derived from a common TP53 mutation. Science, 2021, 371, .	6.0	194
10	Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. Gastroenterology, 2021, 160, 2043-2054.e2.	0.6	17
11	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620.	3.9	88
12	Targeting public neoantigens for cancer immunotherapy. Nature Cancer, 2021, 2, 487-497.	5.7	79
13	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nature Biotechnology, 2021, 39, 1220-1227.	9.4	40
14	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
15	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
16	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nature Communications, 2021, 12, 5271.	5.8	17
17	Revisiting the tumorigenesis timeline with a data-driven generative model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 857-864.	3.3	44
18	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2441-2453.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	3.3	50
20	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science, 2020, 369, .	6.0	351
21	629â€¦Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody. , 2020, , .		0
22	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	5.8	129
23	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology, 2019, 5, 1710.	3.4	383
24	Application of Deep Learning to Pancreatic Cancer Detection: Lessons Learned From Our Initial Experience. Journal of the American College of Radiology, 2019, 16, 1338-1342.	0.9	62
25	An engineered antibody fragment targeting mutant β -catenin via major histocompatibility complex I neoantigen presentation. Journal of Biological Chemistry, 2019, 294, 19322-19334.	1.6	15
26	An analysis of genetic heterogeneity in untreated cancers. Nature Reviews Cancer, 2019, 19, 639-650.	12.8	139
27	Applications of liquid biopsies for cancer. Science Translational Medicine, 2019, 11, .	5.8	151
28	Direct Detection and Quantification of Neoantigens. Cancer Immunology Research, 2019, 7, 1748-1754.	1.6	40
29	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1118.	3.4	152
30	Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue. American Journal of Roentgenology, 2019, 213, 349-357.	1.0	117
31	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Journal of Pathology, 2019, 248, 41-50.	2.1	84
32	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Human Pathology, 2019, 85, 1-9.	1.1	28
33	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut, 2019, 68, 663-671.	6.1	234
34	Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1871-1876.	3.3	48
35	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	6.0	1,872
36	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	5.8	178

#	ARTICLE	IF	CITATIONS
37	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. Nature Communications, 2018, 9, 5410.	5.8	30
38	Minimal functional driver gene heterogeneity among untreated metastases. Science, 2018, 361, 1033-1037.	6.0	223
39	Precancerous neoplastic cells can move through the pancreatic ductal system. Nature, 2018, 561, 201-205.	13.7	96
40	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. Journal of Clinical Oncology, 2018, 36, 3516-3516.	0.8	19
41	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	0.8	4
42	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 145-152.	2.2	34
43	Identification of allosteric binding sites for PI3KÎ± oncogenic mutant specific inhibitor design. Bioorganic and Medicinal Chemistry, 2017, 25, 1481-1486.	1.4	24
44	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics, 2017, 49, 358-366.	9.4	316
45	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4733-4738.	3.3	12
46	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	13.9	451
47	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
48	Necessity Is the Mother of Invention: The Development of Digital Genomics. Clinical Chemistry, 2016, 62, 1668-1669.	1.5	2
49	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
50	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 427-434.	1.4	38
51	Aristolochic Acid in the Etiology of Renal Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1600-1608.	1.1	65
52	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9846-9851.	3.3	178
53	Evaluating the evaluation of cancer driver genes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14330-14335.	3.3	325
54	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	5.8	1,036

#	ARTICLE	IF	CITATIONS
55	Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 11971.	5.8	203
56	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. <i>Clinical Chemistry</i> , 2016, 62, 1054-1060.	1.5	87
57	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
58	Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 265-274.	0.7	80
59	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. <i>Human Pathology</i> , 2016, 53, 8-13.	1.1	31
60	High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2016, 29, 511-515.	2.9	34
61	Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. <i>Gastroenterology</i> , 2016, 150, 931-943.	0.6	208
62	Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 463-469.	1.0	27
63	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. <i>Clinical Cancer Research</i> , 2015, 21, 1944-1950.	3.2	85
64	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9967-9972.	3.3	41
65	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
66	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
67	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	3.3	317
68	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. <i>ACS Nano</i> , 2015, 9, 6861-6871.	7.3	119
69	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	0.8	87
70	The Path to Cancer – Three Strikes and You're Out. <i>New England Journal of Medicine</i> , 2015, 373, 1895-1898.	13.9	269
71	Intraductal papillary mucinous neoplasm in a neonate with congenital hyperinsulinism and a de novo germline SKIL gene mutation. <i>Pancreatology</i> , 2015, 15, 194-196.	0.5	8
72	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. <i>Cancer Discovery</i> , 2015, 5, 43-51.	7.7	1,180

#	ARTICLE	IF	CITATIONS
73	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool.. <i>Journal of Clinical Oncology</i> , 2015, 33, 518-518.	0.8	6
74	<i>Clostridium novyi</i> -NT can cause regression of orthotopically implanted glioblastomas in rats. <i>Oncotarget</i> , 2015, 6, 5536-5546.	0.8	65
75	Structural basis of nSH2 regulation and lipid binding in PI3K β . <i>Oncotarget</i> , 2014, 5, 5198-5208.	0.8	62
76	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
77	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 15-24.	1.5	91
78	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	3.3	578
79	Microbiota organization is a distinct feature of proximal colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18321-18326.	3.3	572
80	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	1.2	44
81	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	5.8	285
82	Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer. <i>Science</i> , 2014, 343, 152-157.	6.0	358
83	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1170-1172.	9.4	247
84	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. <i>Cancer Research</i> , 2014, 74, 3381-3389.	0.4	207
85	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. <i>Annals of Surgical Oncology</i> , 2013, 20, 3802-3808.	0.7	158
86	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	6.0	6,507
87	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. <i>Cancer Research</i> , 2013, 73, 7162-7167.	0.4	214
88	A nanoparticle formulation that selectively transfects metastatic tumors in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14717-14722.	3.3	59
89	Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing. <i>Science Translational Medicine</i> , 2013, 5, 197ra102.	5.8	220
90	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	5.8	264

#	ARTICLE	IF	CITATIONS
91	Massively parallel sequencing (MPS) of circulating DNA in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11015-11015.	0.8	1
92	Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma. <i>Cancer Discovery</i> , 2012, 2, 899-905.	7.7	342
93	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. <i>Nature</i> , 2012, 486, 537-540.	13.7	1,506
94	Somatic mutations in the chromatin remodeling gene <i>ARID1A</i> occur in several tumor types. <i>Human Mutation</i> , 2012, 33, 100-103.	1.1	263
95	FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing. <i>PLoS ONE</i> , 2012, 7, e41162.	1.1	65
96	The Genetic Landscape of the Childhood Cancer Medulloblastoma. <i>Science</i> , 2011, 331, 435-439.	6.0	652
97	<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. <i>Science</i> , 2011, 331, 1199-1203.	6.0	1,504
98	Detection and quantification of rare mutations with massively parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 9530-9535.	3.3	1,016
99	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . <i>Science</i> , 2011, 333, 1154-1157.	6.0	1,568
100	Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations. <i>Science</i> , 2011, 333, 425-425.	6.0	891
101	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
102	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. <i>Nature</i> , 2010, 467, 1114-1117.	13.7	2,184
103	Accumulation of driver and passenger mutations during tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18545-18550.	3.3	742
104	Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma. <i>Science</i> , 2010, 330, 228-231.	6.0	1,090
105	Design and analysis issues in genome-wide somatic mutation studies of cancer. <i>Genomics</i> , 2009, 93, 17-21.	1.3	83
106	<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas. <i>New England Journal of Medicine</i> , 2009, 360, 765-773.	13.9	5,285
107	Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells. <i>Science</i> , 2009, 325, 1555-1559.	6.0	797
108	Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations. <i>Cancer Research</i> , 2009, 69, 6660-6667.	0.4	416

#	ARTICLE	IF	CITATIONS
109	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. <i>Science</i> , 2008, 321, 1807-1812.	6.0	5,230
110	Circulating mutant DNA to assess tumor dynamics. <i>Nature Medicine</i> , 2008, 14, 985-990.	15.2	2,207
111	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	6.0	3,755
112	Comparative lesion sequencing provides insights into tumor evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4283-4288.	3.3	720
113	Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA. <i>Cancer Research</i> , 2007, 67, 9364-9370.	0.4	147
114	The Genomic Landscapes of Human Breast and Colorectal Cancers. <i>Science</i> , 2007, 318, 1108-1113.	6.0	3,049
115	Detection and quantification of mutations in the plasma of patients with colorectal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16368-16373.	3.3	1,049
116	Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8817-8822.	3.3	744
117	Allelic Variation in Human Gene Expression. <i>Science</i> , 2002, 297, 1143-1143.	6.0	618
118	Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. <i>Nature Medicine</i> , 2001, 7, 1111-1117.	15.2	389
119	A Phosphatase Associated with Metastasis of Colorectal Cancer. <i>Science</i> , 2001, 294, 1343-1346.	6.0	601
120	Assessing tumors in living animals through measurement of urinary β -human chorionic gonadotropin. <i>Nature Medicine</i> , 2000, 6, 711-714.	15.2	37
121	Conversion of diploidy to haploidy. <i>Nature</i> , 2000, 403, 723-724.	13.7	248
122	GENETICS: Genetic Testing- Present and Future. <i>Science</i> , 2000, 289, 1890-1892.	6.0	51
123	Role of BAX in the Apoptotic Response to Anticancer Agents. <i>Science</i> , 2000, 290, 989-992.	6.0	843
124	14-3-3 σ is required to prevent mitotic catastrophe after DNA damage. <i>Nature</i> , 1999, 401, 616-620.	13.7	889
125	Mutations of mitotic checkpoint genes in human cancers. <i>Nature</i> , 1998, 392, 300-303.	13.7	1,400
126	Genetic instabilities in human cancers. <i>Nature</i> , 1998, 396, 643-649.	13.7	3,851

#	ARTICLE	IF	CITATIONS
127	Identification of c-MYC as a Target of the APC Pathway. , 1998, 281, 1509-1512.		4,058
128	Less death in the dying. Cell Death and Differentiation, 1997, 4, 242-246.	5.0	14
129	Gatekeepers and caretakers. Nature, 1997, 386, 761-763.	13.7	1,043
130	Activation of beta -Catenin-Tcf Signaling in Colon Cancer by Mutations in beta -Catenin or APC. Science, 1997, 275, 1787-1790.	6.0	3,686
131	Expression of the APC tumor suppressor protein in oligodendroglia. , 1996, 17, 169-174.		227
132	Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics, 1996, 13, 343-346.	9.4	580
133	Expression of the APC tumor suppressor protein in oligodendroglia. , 1996, 17, 169.		2
134	The Molecular Basis of Turcot's Syndrome. New England Journal of Medicine, 1995, 332, 839-847.	13.9	1,060
135	Mutations of the APC(Adenomatous Polyposis Coli) Gene in FAP(Familial Polyposis Coli) Patients and in Sporadic Colorectal Tumors.. Tohoku Journal of Experimental Medicine, 1992, 168, 141-147.	0.5	33
136	Definition of a consensus binding site for p53. Nature Genetics, 1992, 1, 45-49.	9.4	1,944
137	The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature, 1988, 332, 371-374.	13.7	376